Julien Adam

MD PhD, Pathologist at Gustave Roussy Cancer Center, France

[Julien Adam @JAdamMD]

Long-term outcomes of oral vinorelbine in advanced, progressive desmoid fibromatosis and influence of CTNNB1 mutational status https://t.co/uwN3N0C2Tx

[Julien Adam @JAdamMD]

Great overview of multiplex IHC/IF by @md_mariusilie at the Immunopathology symposium organized by the French society of pathology

[Julien Adam @JAdamMD]

NTRK fusions are <1% in most solid tumors, excepted thyroid, cervical cancers and GBM. Their IHC missed some cases with NTRK3 fusions. https://t.co/0K2RFcgwbf

[Julien Adam @JAdamMD]

Amazing view of Paris from the sky tonight!

[Annals of Oncology @Annals_Oncology]

Immune-related pathologic response criteria may be used to standardize pathologic assessment of immunotherapeutic efficacy https://t.co/vpRtZ8FgPx #irPRC

[Vamsi Velcheti, MD MBA FASCO @VamsiVelcheti]

Elegant study using CYTOF by team at NUS singapore— Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates and CD39 expression can differentiate the bystander TILs https://t.co/15HXr4mSRV